Trial Profile
A Phase I/II Study of Anlotinib Combined With Platinum-based Chemotherapy as the First-line Treatment of Patients With Locally Advanced or Advanced Non-Small Cell Lung Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Catequentinib (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 24 Aug 2018 New trial record